{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:32:41Z","timestamp":1789680761268,"version":"4.0.1"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"abstract":"<jats:title>Summary:<\/jats:title>\n                  <jats:p>In this issue, K\u00f6hnke, Karigane, and colleagues applied allele-specific CRISPR\/Cas9 correction in human acute myeloid leukemia samples to dissect the stage-specific functions of DNA methyltransferase 3A (DNMT3A) arginine 882 (R882) mutations. They demonstrate that DNMT3A R882 mutations are required to sustain self-renewal and inflammatory programs in preleukemic cells but become largely dispensable once leukemia is established, while still influencing leukemia stem cell frequency, thereby providing a strong preclinical rationale to reconsider the therapeutic window for targeting DNMT3A-mutant clones early in leukemogenesis.<\/jats:p>\n                  <jats:p>See related article by K\u00f6hnke et al., p. 592<\/jats:p>","DOI":"10.1158\/2159-8290.cd-25-2277","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T08:23:32Z","timestamp":1772439812000},"page":"428-430","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early Driver, Late Bystander: Stage-Specific Roles of DNMT3A R882 Mutations Unveiled in Human AML"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7962-0517","authenticated-orcid":false,"given":"Yubin","family":"Zhou","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01f5ytq51","id-type":"ROR","asserted-by":"publisher"}],"name":"Texas A&M University 1 Institute of Biosciences and Technology, , Houston, Texas."},{"id":[{"id":"https:\/\/ror.org\/01f5ytq51","id-type":"ROR","asserted-by":"publisher"}],"name":"Texas A&M University 2 Department of Translational Medical Sciences, College of Medicine, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5950-9168","authenticated-orcid":false,"given":"Yun","family":"Huang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01f5ytq51","id-type":"ROR","asserted-by":"publisher"}],"name":"Texas A&M University 1 Institute of Biosciences and Technology, , Houston, Texas."},{"id":[{"id":"https:\/\/ror.org\/01f5ytq51","id-type":"ROR","asserted-by":"publisher"}],"name":"Texas A&M University 2 Department of Translational Medical Sciences, College of Medicine, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"2026030203232632700_bib1","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"2026030203232632700_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.stem.2018.01.011","article-title":"Clonal hematopoiesis and evolution to hematopoietic malignancies","volume":"22","author":"Bowman","year":"2018","journal-title":"Cell Stem Cell"},{"key":"2026030203232632700_bib3","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N Engl J Med"},{"key":"2026030203232632700_bib4","first-page":"1590","article-title":"Clonal hematopoiesis: mechanisms driving dominance of stem cell clones","volume":"136","author":"Challen","year":"2020","journal-title":"Blood"},{"key":"2026030203232632700_bib5","first-page":"592","article-title":"DNMT3A R882H is not required for disease maintenance in primary human AML, but is associated with increased leukemia stem cell frequency","volume":"16","author":"K\u00f6hnke","year":"2026","journal-title":"Cancer Discov"},{"key":"2026030203232632700_bib6","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1038\/s41467-024-47398-y","article-title":"Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations","volume":"15","author":"Lu","year":"2024","journal-title":"Nat Commun"},{"key":"2026030203232632700_bib7","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.stem.2016.10.019","article-title":"DNA methylation dynamics of human hematopoietic stem cell differentiation","volume":"19","author":"Farlik","year":"2016","journal-title":"Cell Stem Cell"},{"key":"2026030203232632700_bib8","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/s41588-022-01179-9","article-title":"Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation","volume":"54","author":"Nam","year":"2022","journal-title":"Nat Genet"},{"key":"2026030203232632700_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ccell.2016.05.008","article-title":"Epigenetic perturbations by arg882-mutated DNMT3A potentiate aberrant stem cell gene-expression program and acute leukemia development","volume":"30","author":"Lu","year":"2016","journal-title":"Cancer Cell"},{"key":"2026030203232632700_bib10","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/nm.4210","article-title":"DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling","volume":"22","author":"Guryanova","year":"2016","journal-title":"Nat Med"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/3\/428\/3740957\/cd-25-2277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/3\/428\/3740957\/cd-25-2277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T08:23:33Z","timestamp":1772439813000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/3\/428\/774729\/Early-Driver-Late-Bystander-Stage-Specific-Roles"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,2]]},"published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-25-2277","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}